References
- Stockfleth E, Terhorst D, Braathen L, et al. Guidelines for the management of actinic keratosis. European Dermatology Forum; 2010. Available from: http://www.ensas.ee/docs/management_of_actinic_keratoses.pdf. Accessed March 2015.
- Breuninger H, Bootz F, Hauschild A, et al. Short German guidelines: squamous cell carcinoma. JDDG. 2008;6:S5–8.
- Röwert‐Huber J, Patel M, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156:8–12.
- Feldman SR, Fleischer AB, Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201–7.
- Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115:2523–30.
- Marks R, Rennie G, Selwood T. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795–7.
- Mittelbronn MA, Mullins DL, Ramos‐Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma . Int J Dermatol. 1998;37:677–81.
- Berlin JM. Current and emerging treatment strategies for the treatment of actinic keratosis. CCID. 2010;3:119–26.
- Yu TC, Rahman Z, Ross BS. Actinic keratoses-surgical and physical therapeutic modalities. Cutis. 2003;71:381–4.
- Krawtchenko N, Roewert‐Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5‐fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‐year follow‐up. Br J Dermatol. 2007;157:34–40.
- Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111–22.
- Food and Drug Administration. Full prescribing information for Aldara 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf. Accessed February 2015.
- Food and Drug Administration. Full prescribing information for Zyclara 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022483s006lbl.pdf. Accessed February 2015.
- Food and Drug Administration. Labelling revision for Carac 2003. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20985slr004_carac_lbl.pdf. Accessed February 2015.
- Food and Drug Administration. Labelling revision for Efudex 2005. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/016831s049lbl.pdf. Accessed February 2015.
- Food and Drug Administration. Labelling revision for Solaraze gel 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf. Accessed February 2015.
- LEO pharma. Picato® (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. Available from: http://www.picato.com/_pdf/PrescribingInformation.pdf. Accessed October 2014.
- Food and Drug Administration. Full prescribing information for Picato 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202833lbl.pdf. Accessed February 2015.
- Esmann S, Jemec GB. Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat. 2007;18:53–8.
- Esmann S, Vinding G, Christensen K, Jemec G. Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire. Br J Dermatol. 2013;168:277–83.
- Gholam P, Kroehl V, Enk AH. Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology. 2013;226:253–9.
- Hadley J, Tristani-Firouzi P, Hull C, et al. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg. 2012;38:722–7.
- Dirschka T, Lear JT. Sequential treatment of multiple actinic keratoses with solaraze and actikerall. Case Rep Dermatol. 2014;6:164–8.
- Pflugfelder A, Welter AK, Leiter U, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012;26:48–53.
- Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7:669–73.
- Tan J, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2006;11:195–201.
- Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. JDD. 2010;9:1101–8.
- Serra-Guillén C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol. 2012;66:e131–e7.
- Berman B, Goldenberg G, Hanke CW, et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. JDD. 2014;13:741–7.
- Berman B, Goldenberg G, Hanke W, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. JDD. 2014;13:154–60.
- Cardiff University Section of Dermatology. Dermatology Life Quality Index. Available from: http://www.dermatology.org.uk/quality/dlqi/quality-dlqi.html. Accessed October 20, 2014.
- EuroQol. EQ-5D. Available from: http://www.euroqol.org/. Accessed October 20, 2014.
- Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203–20.
- Rosen R, Marmur E, Anderson L, et al. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther. 2014;4:207–19.
- Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology. 2012;225:45–53.
- Both H, Essink-Bot M-L, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127:2726–39.
- Augustin MT, JH, Mark-Knudsen K, Erntoft S, et al., Effect of ingenol mebutate gel on treatment satisfaction and quality of life in actinic keratosis. 22nd EADV Congress. 2014.
- Bates AS, Davis CR, Takwale A, Knepil GJ. Patient-reported outcome measures in nonmelanoma skin cancer of the face: a systematic review. Br J Dermatol. 2013;168:1187–94.
- Gibbons E, Casanas i, Comabella C, Fitzpatrick R. A structured review of patient-reported outcome measures for patients with skin cancer, 2013. Br J Dermatol. 2013;168:1176–86.
- Samorano LP, Torezan LA, Sanches JA. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol. 2015;29:1822–7.